Abstract
The hypertriglyceridemia of diabetes can be classified into mild to moderate (triglycerides between 150-499 mg/dL) and severe hypertriglyceridemia (triglycerides ≥500 mg/dL). As in any other individuals with hypertriglyceridemia, secondary causes need to be excluded. The management of severe hypertriglyceridemia (chylomicronemia syndrome) includes aggressive reduction of triglycerides with intravenous insulin, fibrates, omega-3 fatty acids, and/or niacin therapy to avert the risk of pancreatitis. In patients with mild to moderate hypertriglyceridemia, the treatment of choice is statin therapy to achieve the lowdensity lipoprotein (LDL) and non-high-density lipoprotein (HDL) target goals. The evidence base would favor niacin therapy in combination with statin therapy to achieve the goals pertaining to LDL cholesterol and non-HDL cholesterol. The data about the combination of fibrate therapy with statin therapy are disappointing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 316-320 |
| Number of pages | 5 |
| Journal | Current Diabetes Reports |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2010 |
Fingerprint
Keywords
- Diabetes
- Dyslipidemia
- Fibrates
- Hypertriglyceridemia
- Niacin
- Statins
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
Management of hypertriglyceridemia in the diabetic patient. / Jialal, Ishwarlal; Amess, William; Kaur, Manpreet.
In: Current Diabetes Reports, Vol. 10, No. 4, 08.2010, p. 316-320.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Management of hypertriglyceridemia in the diabetic patient
AU - Jialal, Ishwarlal
AU - Amess, William
AU - Kaur, Manpreet
PY - 2010/8
Y1 - 2010/8
N2 - The hypertriglyceridemia of diabetes can be classified into mild to moderate (triglycerides between 150-499 mg/dL) and severe hypertriglyceridemia (triglycerides ≥500 mg/dL). As in any other individuals with hypertriglyceridemia, secondary causes need to be excluded. The management of severe hypertriglyceridemia (chylomicronemia syndrome) includes aggressive reduction of triglycerides with intravenous insulin, fibrates, omega-3 fatty acids, and/or niacin therapy to avert the risk of pancreatitis. In patients with mild to moderate hypertriglyceridemia, the treatment of choice is statin therapy to achieve the lowdensity lipoprotein (LDL) and non-high-density lipoprotein (HDL) target goals. The evidence base would favor niacin therapy in combination with statin therapy to achieve the goals pertaining to LDL cholesterol and non-HDL cholesterol. The data about the combination of fibrate therapy with statin therapy are disappointing.
AB - The hypertriglyceridemia of diabetes can be classified into mild to moderate (triglycerides between 150-499 mg/dL) and severe hypertriglyceridemia (triglycerides ≥500 mg/dL). As in any other individuals with hypertriglyceridemia, secondary causes need to be excluded. The management of severe hypertriglyceridemia (chylomicronemia syndrome) includes aggressive reduction of triglycerides with intravenous insulin, fibrates, omega-3 fatty acids, and/or niacin therapy to avert the risk of pancreatitis. In patients with mild to moderate hypertriglyceridemia, the treatment of choice is statin therapy to achieve the lowdensity lipoprotein (LDL) and non-high-density lipoprotein (HDL) target goals. The evidence base would favor niacin therapy in combination with statin therapy to achieve the goals pertaining to LDL cholesterol and non-HDL cholesterol. The data about the combination of fibrate therapy with statin therapy are disappointing.
KW - Diabetes
KW - Dyslipidemia
KW - Fibrates
KW - Hypertriglyceridemia
KW - Niacin
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=77956394971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956394971&partnerID=8YFLogxK
U2 - 10.1007/s11892-010-0124-4
DO - 10.1007/s11892-010-0124-4
M3 - Article
C2 - 20532703
AN - SCOPUS:77956394971
VL - 10
SP - 316
EP - 320
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 4
ER -